 JUPITER, FL ACCESSWIRE October 19, 2021 Jupiter Wellness, Inc. NASDAQ:JUPW, a clinical stage company developing a cannabinoid receptor agonist for the treatment of first degree burns, announced the enrollment and dosing of the first patient in the study. The double-blinded placebo-controlled study will enroll 50 patients with newly diagnosed first degree burns of superficial partial thickness on 10 or less of the patients total body surface area. 